Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$3.34
-0.6%
$3.45
$3.07
$6.66
$198.60M0.511.61 million shs548,236 shs
Hillstream Biopharma Inc. stock logo
CNTN
Hillstream Biopharma
$3.51
+7.3%
$3.42
$1.08
$9.08
$185.27M1.44525,015 shs640,162 shs
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
$1.20
-0.8%
$1.35
$0.78
$3.15
$51.62M0.9740,115 shs24,567 shs
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
$8.85
-0.7%
$7.91
$3.65
$10.99
$201.04M0.8329,999 shs953,891 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-0.60%-5.65%-4.02%-0.60%-35.27%
Hillstream Biopharma Inc. stock logo
CNTN
Hillstream Biopharma
+7.34%+9.69%+6.04%+350,999,900.00%+350,999,900.00%
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
-4.00%-7.69%-31.43%-2.44%+16.49%
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
-0.67%-1.88%+6.88%-1.45%+79.88%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$3.34
-0.6%
$3.45
$3.07
$6.66
$198.60M0.511.61 million shs548,236 shs
Hillstream Biopharma Inc. stock logo
CNTN
Hillstream Biopharma
$3.51
+7.3%
$3.42
$1.08
$9.08
$185.27M1.44525,015 shs640,162 shs
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
$1.20
-0.8%
$1.35
$0.78
$3.15
$51.62M0.9740,115 shs24,567 shs
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
$8.85
-0.7%
$7.91
$3.65
$10.99
$201.04M0.8329,999 shs953,891 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-0.60%-5.65%-4.02%-0.60%-35.27%
Hillstream Biopharma Inc. stock logo
CNTN
Hillstream Biopharma
+7.34%+9.69%+6.04%+350,999,900.00%+350,999,900.00%
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
-4.00%-7.69%-31.43%-2.44%+16.49%
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
-0.67%-1.88%+6.88%-1.45%+79.88%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
2.00
HoldN/AN/A
Hillstream Biopharma Inc. stock logo
CNTN
Hillstream Biopharma
1.00
SellN/AN/A
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
2.00
Hold$8.00566.67% Upside
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
2.86
Moderate Buy$17.1793.97% Upside

Current Analyst Ratings Breakdown

Latest ESLA, KPTI, CNTN, and ACB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/6/2026
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
Boost Price TargetBuy$8.00 ➝ $13.00
5/1/2026
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
UpgradeSell (E+)Sell (D-)
4/29/2026
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
DowngradeSell (D-)Sell (E+)
4/27/2026
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
Reiterated RatingOverweight$8.00 ➝ $16.00
3/30/2026
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
Reiterated RatingOverweight$12.00 ➝ $8.00
3/25/2026
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
Lower Price TargetOutperform$21.00 ➝ $15.00
3/25/2026
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
Lower Price TargetBuy$15.00 ➝ $8.00
3/10/2026
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
UpgradeStrong-Buy
3/9/2026
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
Initiated CoverageBuy$28.00
3/9/2026
Hillstream Biopharma Inc. stock logo
CNTN
Hillstream Biopharma
Initiated CoverageSell (E+)
2/18/2026
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
Reiterated RatingBuy$15.00
(Data available from 5/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$246.72M0.80$0.61 per share5.50$7.78 per share0.43
Hillstream Biopharma Inc. stock logo
CNTN
Hillstream Biopharma
N/AN/AN/AN/A$10.92 per shareN/A
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
N/AN/AN/AN/A($0.27) per shareN/A
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
$146.07M1.37N/AN/A($16.00) per share-0.55
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$1.63M-$1.08N/AN/AN/A-23.46%-0.04%-0.03%6/17/2026 (Estimated)
Hillstream Biopharma Inc. stock logo
CNTN
Hillstream Biopharma
-$35.92M-$3.99N/AN/AN/AN/A-35.59%-27.05%N/A
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
-$13.06M-$0.35N/AN/AN/AN/AN/A-430.91%5/13/2026 (Estimated)
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
-$196.04M-$16.62N/AN/AN/A-134.21%N/A-122.29%5/14/2026 (Estimated)

Latest ESLA, KPTI, CNTN, and ACB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2026Q1 2026
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
-$1.45N/AN/AN/A$31.40 millionN/A
5/13/2026Q1 2026
Hillstream Biopharma Inc. stock logo
CNTN
Hillstream Biopharma
N/A-$0.23N/A-$0.23N/AN/A
5/13/2026N/A
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
-$0.0840N/AN/AN/AN/AN/A
3/31/2026Q4 2025
Hillstream Biopharma Inc. stock logo
CNTN
Hillstream Biopharma
N/A$0.54N/A$0.54N/AN/A
3/18/2026Q4 2025
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
-$0.18-$0.01+$0.17-$0.01N/AN/A
2/13/2026Q4 2025
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
-$2.26-$2.23+$0.03-$5.71$33.16 million$34.08 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Hillstream Biopharma Inc. stock logo
CNTN
Hillstream Biopharma
N/AN/AN/AN/AN/A
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
N/AN/AN/AN/AN/A
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.06
3.06
1.48
Hillstream Biopharma Inc. stock logo
CNTN
Hillstream Biopharma
N/A
5.29
5.29
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
N/A
0.12
0.12
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
N/A
1.12
1.08

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Hillstream Biopharma Inc. stock logo
CNTN
Hillstream Biopharma
1.16%
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
0.35%
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
66.44%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,13059.11 million59.10 millionOptionable
Hillstream Biopharma Inc. stock logo
CNTN
Hillstream Biopharma
256.66 million52.86 millionN/A
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
N/A42.67 million19.16 millionNot Optionable
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
38022.55 million22.17 millionOptionable

Recent News About These Companies

Karyopharm: Putting The Phase 3 Trial In Context

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$3.34 -0.02 (-0.60%)
Closing price 05/13/2026 04:00 PM Eastern
Extended Trading
$3.34 +0.00 (+0.12%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Hillstream Biopharma stock logo

Hillstream Biopharma NASDAQ:CNTN

$3.51 +0.24 (+7.34%)
Closing price 05/13/2026 04:00 PM Eastern
Extended Trading
$3.51 0.00 (0.00%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2019 and is based in Bridgewater, New Jersey.

Estrella Immunopharma stock logo

Estrella Immunopharma NASDAQ:ESLA

$1.20 -0.01 (-0.83%)
Closing price 05/13/2026 04:00 PM Eastern
Extended Trading
$1.20 +0.00 (+0.08%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Karyopharm Therapeutics stock logo

Karyopharm Therapeutics NASDAQ:KPTI

$8.85 -0.06 (-0.67%)
Closing price 05/13/2026 04:00 PM Eastern
Extended Trading
$8.75 -0.10 (-1.12%)
As of 05/13/2026 07:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.